Promis Neurosciences Inc. · NASDAQ:PMN
Promis Neurosciences — Technical Presentation (July 2026)
27 slides from Promis Neurosciences's technical presentation, Jul 28, 2026
Slide 1: PRECISE-AD PMN310 Phase 1b Blinded 6-Month Interim Analysis
PRECISE-AD PMN310 · PHASE 1b BLINDED 6-MONTH INTERIM ANALYSIS Safety & Biomarker Assessment Update Blinded Interim Analysis Topline results expected Q1 2027 1
Slide 2: Forward-Looking Statements & Disclaimers
LEGAL DISCLOSURES Forward-Looking Statements & Disclaimers Blinded Interim Analysis Topline results expected Q1 2027 This slide deck may contain certain forward-looking information and “forward-looking statements” that are made pursuant to the safe harbor provisions of the Private Securities Litigat
Slide 3: Table of Contents
Table of Contents 3 Slides 4-5: Company Overview, KOL Bios Slides 6-11: PRECISE-AD Phase 1b Trial Design and Patient Demographics Slides 24-27: Summary and Conclusions Slides 12-16: Blinded Safety Assessment Slides 17-23: Blinded Biomarker Assessment
Slide 4: Presenters & KOL Participants
Presenters & KOL Participants PRESENTERS Neil Warma President & CEO ProMIS Neurosciences Dr. Larry Altstiel Chief Medical Officer (M.D., Ph.D.) ProMIS Neurosciences KEY OPINION LEADER Dr. Will Mantyh Behavioral Neurologist University of Minnesota Focused on early detection and diagnosis of Alzheimer
Slide 5: Company Snapshot
COMPANY SNAPSHOT Clinical-stage biotechnology company with a pipeline designed to selectively target specific, disease-causing misfolded proteins Unique selectivity may create potential to address the unmet need for safer, more efficacious therapies. PMN : NASDAQ Cambridge, MA TOP-LINE DATA Early Q1
Slide 6: Execution on Track, Progressing Quickly Toward Topline Results
TRIAL MILESTONES Execution on Track, Progressing Quickly Toward Topline Results DEC 2025 Enrollment n = 144 complete JUN 2026 6-Month Dosing complete EARLY Q3 2026 Interim Data this presentation DEC 2026 12-Month Dosing expected to complete for all patients EARLY Q1 2027 Topline Results final readou
Slide 7: PRECISE-AD Study Design & Patient Demographics
PRECISE-AD Study Design & Patient Demographics 7
Slide 8: PRECISE-AD: Phase 1b Trial Design
PRECISE-AD: Phase 1b Trial Design KEY STUDY PARAMETERS & PATIENT DEMOGRAPHICS Study PRECISE-AD · Phase 1b Patient population Mild Cognitive Impairment (MCI) due to AD / early AD Total enrolled 144 patients Safety-evaluable 136 patients RANDOMIZATION · 3:1 DRUG TO PLACEBO Drug ~75% DOSE COHORTS · MUL
Slide 9: Subjects Evaluated to Confirm MCI due to AD or Early AD
TRIAL EXECUTION & DEMOGRAPHICS Subjects Evaluated to Confirm Mild Cognitive Impairment (MCI) due to AD or Early AD CONFIRMATION CRITERIA Clinical Criteria NIA-AA criteria: MCI due to AD or mild AD dementia 100% Amyloid-Positive Confirmed on PET imaging Cognitive Staging MMSE* 20–30 & CDR Global 0.5–
Slide 10: PRECISE-AD: Enrollment Consistent with Real World AD Population
TRIAL DEMOGRAPHICS PRECISE-AD: Enrollment Consistent with Real World AD Population 11% APOE4/4 Homozygous Highest ARIA-risk subgroup with plaque-binding therapies 50% APOE4 Carrier (1 allele) E2/E4, E3/E4, E4/E3 and E4/E2 combined 61% Total APOE4 Carriers $Q\SDUWLFLSDQWZLWK•$32(DOOHOH WHY TH
Slide 11: Many Patients are Currently Well Beyond 6 Months of Treatment
SAFETY Many Patients are Currently Well Beyond 6 Months of Treatment TREATMENT EXPOSURE TO DATE 0 (initiation) 6 mo 9 mo 12 mo • All patients have been treated for at least 6 months. Many (~49%) have completed all 12 doses • 144 subjects were enrolled, 136 have been included in this safety analysis
Slide 12: Blinded Safety Assessment
12 Blinded Safety Assessment
Slide 13: Favorable Safety Data, Observed Across Key Measures
INTERIM SAFETY · 6-MONTH BLINDED Favorable Safety Data, Observed Across Key Measures 6-month blinded interim · N = 144 dosed, 136 safety-evaluable · a representative population 0.0% ARIA-E The most severe treatment driven form of ARIA No treatment-related serious AEs Across all genotypes No treatmen
Slide 14: Cumulative ARIA-E Over Time: Zero Edema Observed First 6 Months
TIME-MATCHED SAFETY Cumulative ARIA-E Over Time: Zero Edema Observed First 6 Months ARIA-E (the most serious ARIA type) has been observed to occur almost entirely in the first six months of dosing. Comparator ARIA-E plateaus after the first few months; rates are time-matched to published data where
Slide 15: Cumulative Total ARIA Over Time: Tracks the Placebo Range
TIME-MATCHED SAFETY Cumulative Total ARIA Over Time: Blinded PRECISE-AD Data Tracks the Placebo Range Reported in Other Trials Approved anti-amyloids accrue ARIA steeply in the first months of dosing, with 90%+ ARIA-E occurring in the first 6 months. Comparator rates are time-matched to published da
Slide 16: APOE4: Higher-risk Patient Population for ARIA-E
ARIA risk rises sharply with APOE4 carrier status. Approved drugs carry boxed warnings and the worst risk/benefit profile, especially for homozygotes, who represent ~15% of patients. ARIA-E rates at 6 months by APOE4 genotype Genotype Lecanemab* PMN310 Noncarrier ~5% 0% APOE4 Heterozygote ~10% 0% AP
Slide 17: Blinded Biomarker Assessment
12 Blinded Biomarker Assessment
Slide 18: Two complementary biomarkers: plasma pTau217 and CSF MTBR-tau243
6-MONTH BLINDED INTERIM ANALYSIS Two complementary biomarkers: plasma pTau217 and CSF MTBR-tau243 Presenting 6-month blinded interim data on two biomarkers chosen to bracket the disease cascade. UPSTREAM · PLASMA · AMYLOID-DRIVEN Plasma pTau217 The earliest-moving, best-validated plasma marker of AD
Slide 19: pTau217: early blood-based readout of AD biology
BIOMARKER RATIONALE pTau217: early blood-based readout of AD biology What it measures Disease progression: a downstream marker of amyloid-positive AD pathology and tau pathway activation. Why it matters In untreated (placebo) patients, pTau217 rises ~6% over 18 months. A decline in pTau217 would be
Slide 20: PRECISE-AD Results: Plasma pTau217 declined steadily through Day 169
6-MONTH BLINDED ANALYSIS · PLASMA PRECISE-AD RESULTS: Plasma pTau217 declined steadily through Day 169 PRECISE-AD Mean % change from baseline over time -25 -20 -15 -10 -5 0 5 0 29 85 141 169 % change from baseline Study day Linear trend PRECISE-AD patients with a day-169 decline 68.5% 31.5% 0 20 40
Slide 21: CSF MTBR-tau243: tangle-specific marker of AD pathology
BIOMARKER RATIONALE CSF MTBR-tau243: tangle-specific marker of AD pathology What it measures A CSF marker of tauopathy, the pathology most closely tied to symptoms. Why it’s strong Correlates with tau-tangle burden and cognition comparable to tau-PET, and more strongly than other CSF markers. Tau pa
Slide 22: PRECISE-AD Results: CSF MTBR-tau243 declined steadily through Day 169
6-MONTH BLINDED ANALYSIS · CSF PRECISE-AD RESULTS: CSF MTBR-tau243 declined steadily through Day 169 PRECISE-$'0HDQFKDQJHVFUHHQĺ'D\ -25 -20 -15 -10 -5 0 5 Screen Day 169 % change from baseline Timepoint PRECISE-AD: Patients with a Day-169 decline 62.5% 37.5% 0 20 40 60 80 Declined Increa
Slide 23: Biomarker Summary: Two biomarkers, one coherent 6-month signal
BIOMARKER SUMMARY Two biomarkers, one coherent 6-month signal UPSTREAM · PLASMA pT217 declined through Day 169 A steady overall decline of 15% vs baseline with ~68% of all patients showing a reduction, indicating potential improvement. This tracks the 75% (3:1) randomization pattern, in a blinded an
Slide 24: Summary & Conclusions
ProMis™ Neurosciences Summary & Conclusions
Slide 25: A Differentiated, Precision Approach to Alzheimer's
CONCLUSION A Differentiated, Precision Approach to Alzheimer’s — With a Clear Path Forward PRECISE-AD’s blinded interim analysis shows favorable safety data and early, mechanism-consistent biomarker signals, supporting a differentiated approach for patients underserved by approved anti-amyloid thera
Slide 26: Topline results early Q1 2027
Topline results early Q1 2027 Favorable safety profile No ARIA-E, zero SAEs — across all genotypes. Early biomarker signals Directional trends consistent with potential target engagement. Oligomer-selective MOA Designed to decouple efficacy from ARIA liability with precision selectivity. PMN : NASDA
Slide 27: For further information, contact
NASDAQ: PMN For further information, contact: info@promisneurosciences.com 26
ProMIS Neurosciences — Technical Presentation (July 2026) on 6ix